SINOVAC, HKU-CTC & GHK partner for Omicron-specific vaccine trials
Category: #health  By Mateen Dalal  Date: 2022-07-05
  • share
  • Twitter
  • Facebook
  • LinkedIn

SINOVAC, HKU-CTC & GHK partner for Omicron-specific vaccine trials

The Gleneagles Hospital Hong Kong (GHK or Gleneagles) recently held an event to introduce a clinical trial for assessing the security and immunogenicity of Omicron-targeted COVID-19 inactivated vaccine developed by SINOVAC which will be used as a booster shot in adults, in anticipation of offering scientific proof for future immunization strategy.

Credible sources cite that the study is headed by the University of Hong Kong Clinical Trials Centre's (HKU-CTC) medical research team in association with Gleneagles.

A total of 300 adult volunteers aged 18 or above, who have been jabbed with two or three doses of mRNA COVID-19 or inactivated vaccine, will be recruited in this study.

Prof. Ivan Hung Fan-Ngai, a Clinical Prof. at the Department of Medicine and Asst. Dean (Clinical Curriculum & Assessment) at the LKS Faculty of Medicine at the HKUMed (University of Hong Kong) stated during the event that everyone around the world knows that vaccination is one of the most efficient ways to handle infectious diseases.

He further said that at present, Omicron is continuously spreading across the world. Based on this, the clinical trial is expected to effectively enhance and promote vaccine research and vaccination administration.

In December 2021, SINOVAC obtained the Omicron variant's sample and then actively promoted the research and development of its inactivated COVID-19 vaccine.

As per preclinical research, the vaccine is effective and has been found safe in animals.

Following this, the booster immunization clinical trial for Omicron was then approved by the HKU GHK IRB (Institutional Review Board) on April 2022 and by the Pharmacy and Poisons Board of Hong Kong, empowering them to carry out the clinical study for augmenting the immunity of people against the new variant of COVID-19 in Hong Kong.

Source Credit - https://www.businesswire.com/news/home/20220704005146/en/SINOVAC-joins-hands-with-HKU-CTC-research-team-and-Gleneagles-Hospital-Hong-Kong-to-kick-off-a-clinical-trial-of-an-Omicron-specific-inactivated-vaccine-for-booster-use-in-Hong-Kong-China

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Reliance forays into partnerships, acquisitions & R&D for Green Energy
Reliance forays into partnerships, acquisitions & R&D for Green Energy
By Mateen Dalal

Mukesh Ambani, Chairman and Managing Director of Reliance Industries, reportedly announced that the firm has entered several partnerships, including equity investments, with regional and international corporations. The firm selected entities that ...

Braxia Scientific extends telehealth prowess with KetaMD acquisition
Braxia Scientific extends telehealth prowess with KetaMD acquisition
By Mateen Dalal

Toronto-based mental health specialist Braxia Scientific is reportedly planning to acquire KetaMD to expand its telehealth capabilities, especially its tech-based ketamine treatments. The deal is expected to be around USD 6 million. For those unaw...

Instagram to allow users to shop and pay directly using DMs
Instagram to allow users to shop and pay directly using DMs
By Mateen Dalal

Social networking platform Instagram is all set to enable its users to make a direct purchase via chats, also known as DMs (Direct Messages). According to the company’s blog post, this feature will be available for some selected qualified sm...